Technological advances have yielded a wealth of biomarkers that have the potential to detect chronic diseases such as cancer. However, most biomarkers considered for further validation turn out not to have strong enough performance to be used in clinical practice. Group sequential designs that allow early termination for futility may be cost-effective for biomarker studies based on biobanks of stored specimens. Previous studies proposed a group sequential design for the validation of a single biomarker. In this article, we adapt a 2-stage design to the setting where a panel of candidate biomarkers are under investigation. Conditional estimators of the clinical performance are proposed under an updated risk model that uses all accrued data, and can be computed through resampling procedures. Under a special case where a multivariate binormal distribution applies for biomarkers following a suitable transformation, these estimators have analytical forms, alleviating the computational burden while retaining statistical efficiency. Performance of the proposed 2-stage design and estimators are compared with a traditional fixed-sample design and an existing 2-stage design that allows early termination but does not update the risk model with accrued information. Our proposed design and estimators show an ability to reduce sample size when the biomarker panel is not promising, while controlling rejection rate and gaining efficiency when the panel is promising. We apply the proposed methods to a biomarker panel development for the detection of high-grade prostate
INTRODUCTION
Technological advances have yielded a wealth of biomarkers that have the potential for early detection of chronic diseases such as cancer. The evaluation of diagnostic biomarkers often undergoes 5 phases (Pepe and others, 2001) . Take a specific cancer as an example. A phase 1 study is usually a pre-clinical study to identify biomarkers that are differentially expressed in tumor and normal tissues; a phase 2 study 800 S. ZHAO AND OTHERS retrospectively validates performance of biomarkers in subjects with known disease status; a phase 3 study is usually a retrospective longitudinal study to evaluate the ability of biomarkers to detect disease early; a phase 4 study involves a prospective screening test on relevant population to assess sensitivity and specificity; and a phase 5 study is usually a population-based screening study to estimate cancer mortality reduction. Rigorous and efficient study designs for the early phases are important but frequently overlooked, posing an obstacle for biomarker research.
In a phase 1 biomarker study, a large pool of biomarkers, for example based on genomic or proteomic studies, may be evaluated. False signals can be expected because of the large number of tests. When the candidate biomarkers are further evaluated in a phase 2 study, many of them will not meet performance criteria to continue to later phases. Different from clinical trials which may sequentially enroll patients, a phase 2 biomarker study is usually based on biobanks of stored biospecimens. An early termination option in a phase 2 study is desirable to conserve specimens and minimize assay cost. A 2-stage group sequential design for a phase 2 study has been proposed for this purpose (Pepe and others, 2009) . The cases and controls are randomly divided into 2 stages. Samples assigned to stage 1 are assayed to test whether the biomarker performance passes a minimal acceptance criterion. If not, this biomarker is not considered further and samples assigned to stage 2 are saved for other purposes. Otherwise, stage 2 samples are assayed and analyzed. For biomarkers that complete both stages, one is interested in obtaining valid estimates of their clinical performance, such as sensitivities and specificities. These performance parameters can facilitate the design of a phase 3 study, for example in sample size determination. When such a sequential design is implemented, it is necessary to take the early termination possibility into account, to avoid overestimation of performance parameters. Pepe and others (2009) proposed conditional estimators under a 2-stage design for the sensitivity and specificity of a dichotomous biomarker. Koopmeiners and others (2012) extended this design and the conditional estimators to a continuous biomarker. Based on saving specimens and reducing cost when a biomarker is not useful and more efficient performance parameter estimates for a promising biomarker, this design and the corresponding conditional estimators have become standard in biomarker evaluation in the National Cancer Institute (NCI)'s Early Detection Research Network (EDRN).
For many diseases, such as prostate cancer, it has been recognized that a single biomarker usually does not have adequate performance to be used for population screening. When properly combined, a panel of biomarkers may have greater potential for adequate performance. However, validation of a biomarker panel is more challenging compared with that for a single biomarker. Overfitting can be expected if the same dataset is used for both developing a risk model and evaluating its performance. Recently, the Institute of Medicine Omics Committee proposed guidelines for a 2-phase marker panel development and validation process, which includes a discovery and test validation phase and an evaluation for clinical use phase. To avoid overfitting, the first phase consists of 2 stages: a discovery stage and a validation stage. A risk model is developed on training samples in the discovery stage, followed by a "lock-down" of all computational procedures. In the validation stage, the risk model is tested on independent blinded samples. For a pivotal trial, using a lock-down model is preferred to maintain simplicity, and there is typically no early termination option. However, for a biomarker panel discovery study with the goal of developing a robust and optimal biomarker panel, allowing early termination for futility and updating the risk model with complete data are desirable study features. Koopmeiners and Vogel (2013) proposed a 2-stage design for this purpose. They suggest a risk model be developed in stage 1, and a Receiver Operating Characteristic (ROC) curve be constructed on the same set of data to provide the optimistic estimate of performance. If the performance achieves a pre-specified minimal criterion, the risk model is evaluated on stage 2 data to estimate its performance parameters. This study design allows model selection in stage 1 to accommodate a large number of candidate biomarkers, and could improve efficiency over fixed-sample design by allowing early stopping. However, since this design is proposed for a large number of biomarkers, the risk model is not updated with complete data to avoid complication of model selection in both stages. In situations where the number of candidate biomarkers is relatively small and model selection is not needed, the proposed design and estimators can be inefficient. In addition, since the termination decision is based on an over-fitted ROC curve, type I error may not be well controlled.
In this manuscript, we propose a sequential 2-stage design for a phase 2 biomarker panel development study that allows early termination for futility. Accompanying this design, we also provide estimators of both the risk model and the corresponding performance parameters that make full use of available data. In Section 2, we describe this study design and the conditional estimators. Resampling procedures are used to compute these estimates. We also discuss a simplification of computational procedures under a multivariate binormal distribution special case. In Section 3, we present simulation studies to compare our proposed approach with existing methods. In Section 4, we apply the proposed method to an EDRN prostate cancer biomarker study that aims to develop a biomarker panel for the detection of high-grade prostate cancer. We summarize our work with discussion in Section 5.
METHODS

Two-stage design
We consider a panel of k biomarkers X, where X is a vector of length k. The study aims to assess whether this panel can be used in clinical practice for the detection of a disease D and to develop a risk model f with parameter β. Here, we restrict our discussion to a small set of candidate biomarkers, so no model selection is required. Extensions to allow model selection are mentioned in Section 5.
We assume an underlying logistic model:
According to McIntosh and Pepe (2002) , the optimal risk score is r (X) = P(D = 1|X), and under the logistic model it can be written as
which is a monotone function of W = X T β. Since ROC curve is invariant under monotone transformations, we will focus on the performance of W . In the following description and simulation, we use ROC(t), 0 < t < 1, which is the sensitivity at specificity 1 − t, as an example of a performance parameter of interest. Other performance parameters, such as the inverse of ROC(t) (ROC −1 (t)), the area under the ROC curve (AUC), partial AUC, positive predictive value or negative predictive value can be considered similarly.
A minimal desirable performance criterion needs to be specified beforehand. This criterion can reflect the performance of current standard practice, with a new test only acceptable if its performance is better than the current standard. For example, we may want the test to have sensitivity at least γ 0 when the specificity is 1 − t. That is,
For a fixed-sample phase 2 biomarker study, samples are randomly divided into a training and a validation dataset. A risk model withβ fixed is built on the training dataset and evaluated on the validation dataset. We accept H 0 if the upper limit of the 95% confidence interval for ROC(t) is smaller than γ 0 . In contrast, for a 2-stage design, one first randomly assigns m samples to stage 1 and the remaining n − m to stage 2. Stage 1 samples are first assayed for their biomarker values X 1 , X 2 , . . . , X m . There are several approaches to develop a risk model based on stage 1 samples, such as K -fold cross-validation. Here, we propose a highly stable bootstrap approach, which is described in Section 2.2 as an inner bootstrap procedure. If the upper limit of the confidence interval ofROC s1 (t) is less than γ 0 , we conclude there is not enough evidence to support this panel for further evaluation (C = 0). Otherwise, the study continues to stage 2 (C = 1), and the remaining n − m samples are assayed for their biomarker values X m+1 , X m+2 , . . . , X n . The procedures for estimating β and ROC(t) upon study completion are described in Section 2.3. Copas and Corbett (2002) discussed the magnitude of overestimation of ROC(t) if a risk model is developed and evaluated on the same dataset, and pointed out that the overestimation is largest with the high specificities that are usually of the most interest. However, for most biomarker studies, especially for expensive biomarkers, sample size is usually not very large. Further dividing these subjects into a training and a validation dataset may result in efficiency loss and unstable estimates. Even if one starts with a relatively large study, e.g. n = 1600 as will be discussed in Section 3, a random assignment of half patients to stage 1 will reduce the sample size to 800, and training and validation datasets will only have 400 subjects, respectively. Also, it is known that maximumlikelihood estimates (MLEs) of logistic regression parameters can have non-trivial bias when sample size is small (Cordeiro and McCullagh, 1991) , which can result in an underestimation of ROC(t). Thus, methods that avoid sample size reduction are of interest.
An inner bootstrap procedure for performance estimation
Here, we propose a bootstrap approach to develop a risk model and test its performance while making full use of available data. This approach will be used as the basis for the estimation procedure of the proposed 2-stage design, and we refer to it as an inner bootstrap procedure. We describe this procedure with an underlying logistic regression model, but it applies readily to other classes of models. For the lth bootstrap sample, we have the following steps:
Step A: Sample m subjects with replacement, and denote the data as
Step B: A logistic regression model is fitted to
Step C: Risk scoresŵ
s1 are computed for subjects who are not sampled in Step A, that is
Step D:ROC This procedure is repeated for a large number of times (L). Then we estimatê
A percentile bootstrap confidence interval can be formed to decide whether to continue to stage 2. This procedure is expected to provide an unbiased estimate, and it is computationally easy to implement. Also we expect this procedure to be efficient, since there is no sample size reduction in calculatingβ (l) s1 , and averaging over bootstrap replications allows us to use information of all m subjects. Although described based on stage 1 data, this inner bootstrap procedure can also be applied to stage 2 data, and to combined stage 1 and 2 data, as will be amplified below. 
Estimation following completion of a 2-stage design
If after performing the inner bootstrap procedure on the m stage 1 subjects, the biomarker panel showed sufficient promise, samples of the remaining n − m stage 2 subjects are then assayed. We now consider how to estimate β and ROC(t) for a study that completes both stages. As discussed in Pepe and others (2009) and Koopmeiners and others (2012) , for a single biomarker, there are several approaches, including an estimate based on all data, an estimate based on stage 2 data only, and a conditional estimate that takes the early termination possibility into account. All 3 estimates can be extended to the evaluation of a biomarker panel. Their implementation and corresponding properties are discussed below.
First, upon completion of a 2-stage study, we can estimate β and ROC(t) using the inner bootstrap procedure on all subjects {X 1 , X 2 , . . . , X n ; D 1 , D 2 , . . . , D n }, and denote these estimates asβ all,C=1 and ROC all,C=1 (t). Here, we treat the 2-stage study as a fixed-sample study, ignoring the fact that stage 1 data has to pass a minimal acceptable criterion for a study to continue to completion. These estimates are positively biased, because only studies that have high performances in stage 1 can continue to stage 2. To simplify the notation, we suppress the condition C = 1 in the following discussion.
We may also estimate the ROC curve with stage 2 data
. . , D n }, again with the inner bootstrap procedure. We denote these estimates asβ s2 andROC s2 (t). These estimates are also conditional on C = 1, but they are expected to be unbiased, since stage 1 and 2 data are independent. However, they can be inefficient due to the lack of use of stage 1 data.
Unbiased conditional estimators, similar to those proposed by Pepe and others (2009) and Koopmeiners and others (2012) for a single biomarker study, can improve efficiency compared with estimators using solely stage 2 data. The conditional estimators are defined aŝ
It is straightforward to prove thatβ cond and ROC cond (t) are unbiased for β and ROC(t), and they have smaller variances thanβ s2 and ROC s2 (t), respectively. For example, for a fixed t,
These estimators do not have closed forms for a general biomarker distribution. Hence, we propose the following resampling steps to estimate them: for the jth resampling,
Step 1: From the n subjects, randomly sample m subjects to serve as the pseudo stage 1 data, and the remaining n − m as the pseudo stage 2 data.
Step 2: Use the inner bootstrap procedure on the pseudo stage 1 data to calculateβ [ j] s1 (t), ROC [ j] s1 (t) and the corresponding 95% confidence interval. If the upper limit of the 95% confidence interval of ROC [ j] s1 (t) is lower than γ 0 , we terminate with C
[ j] = 0; otherwise, we continue to stage 2 with
Step 3: If C [ j] = 1, the same inner bootstrap procedure is used on the pseudo stage 2 data to calculatê
s2 (t) and ROC [ j] s2 (t). 
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We repeat this procedure for a large number of times (J ). Then we estimatê
We call this resampling procedure an outer bootstrap procedure. In order to provide percentile confidence intervals forβ cond and ROC cond (t), another resampling layer is needed. This resampling procedure is similar to the non-parametric bootstrap approach in Pepe and others (2009) , with extension to a biomarker panel by 3 nested bootstrap resampling procedures.
Special cases under multivariate binormal distributions
In the previous discussion, we described a 2-stage design and an inference procedure based on a widely used logistic regression model. The proposed conditional estimates at study completion can be calculated through the outer bootstrap procedure. Since each outer bootstrap replication involves the inner bootstrap, the computational burden can be heavy, especially for confidence interval calculation. Also, if the underlying model is not a logistic model, W = X T β from the logistic model may be a suboptimal score, leading to an underestimation of the panel performance. In this section, we describe a simplification of the inner bootstrap procedure under a multivariate binormal distribution where the optimal risk score can be derived analytically. The proposed outer bootstrap procedure and the estimators at study completion follow only with minor changes.
We assume the underlying distribution of biomarkers X, or properly transformed X, is multivariate binormal:
where M 0 , M 1 are mean vectors of length k and V 0 , V 1 are k × k variance matrices. Under this model, the optimal risk score r (X) = P(D = 1|X) is a monotone function of
Under the special case that
, which is also binormally distributed. Thus, ROC(t) has an analytic form: (t) . Under this common variance special case, the optimal score W has the same linear form as arose from a logistic regression model. Hence replacing the inner bootstrap approach with direct estimates of β and ROC(t) can be expected to result in small changes in point estimates, but also to improve efficiency of the estimates as well as the computational simplicity. For a general case of V 0 = V 1 , W is a quadratic form of X rather than a linear combination. This indicates that the logistic model is not correct under this distribution and using the quadratic combination W can lead to better accuracy under the binormal model. Once again, one can simplify the bootstrap procedure. First one can estimate M 0 , M 1 , V 0 , V 1 as sample means and variances from the corresponding disease group. Although one is not able to write the analytic form of ROC(t) because W has a quadratic form of X, we can simulate a large dataset of multivariate binormal random variables withM 0 ,M 1 ,V 0 ,V 1 as the corresponding means and variances, and then calculate ROC(t) using an empirical estimator. Similar to the common variance special case, the outer bootstrap procedure is modified by replacing the inner bootstrap approach by this numerical approach. We note that, under this setting, mis-specification of a logistic model will provide a suboptimal risk model for the panel and underestimation of its performance. We expect this parametric bootstrap approach will tend to produce accurate risk models and efficient performance estimates in many application settings.
Furthermore, this parametric bootstrap approach is not restricted to the special case of binormal distribution. If the distribution of X or transformed X follows a known parametric distribution with parameters A, we can use similar methods to estimate A with appropriate data and simulate datasets to obtain empirical estimates of ROC curves. Although the simulation may have similar computational complexity as the inner bootstrap approach when the parametric distribution is complicated, this parametric bootstrap approach can be expected to provide more efficient estimates if the parametric model is well chosen.
SIMULATION
We now examine the performance of the proposed 2-stage group sequential design and the conditional estimators with simulation studies.
We first simulated X from a multivariate normal distribution with k = 2, means 0, variances 1 and correlation 0.2. Disease status D was simulated from a logistic model with α = 1, β T = (0.5, 1). We focus on ROC(0.2) as an example, which has value 0.591 in this setting. We vary the sample size as n = 1600, 800, 400 and 200, and half of the subjects were assigned to stage 1 (i.e. m = n/2). Minimal acceptance γ 0 for ROC(0.2) ranged from = 0.55 to 0.7 across simulation configurations. A similar simulation was repeated for k = 4. Biomarker values X were simulated from a multivariate normal distribution with means 0, variances 1 and correlations 0.2. Disease status D was simulated from a logistic model with α = 1, β T = (0.4, 0.5, 0.5, 0.5). The targeted ROC(0.2) in this context is 0.590. All the simulations are repeated 1000 times. Simulation results for ROC(0.2) are summarized in Table 1 , and those forβ are provided in Table 1 of the supplementary material available at Biostatistics online.
With a fixed-sample design, the estimate for ROC(0.2) presents some bias with smaller sample sizes, due to bias in logistic regression parameter estimates. This bias becomes stronger as number of biomarkers increases. Comparing our 2-stage design with the design described in Koopmeiners and Vogel (2013) shows that our design has a higher continuation rate. When γ 0 increases to 0.59, which is the true ROC(0.2), the Koopmeiners and Vogel approach rejects about 50% of simulated datasets, due to defining the rejection region in terms of point estimate. Our approach only rejects about 1.1-3% of simulated studies, which is close to the expected 2.5% under H 0 . This is a desirable property in the context of motivating research projects, and it derives from defining the continuation region in terms of the upper limit of 95% confidence interval. Although minimizing cost and saving samples is the main objective of a sequential design, it is also important that useful biomarker panels proceed for full evaluation. Our approach balances the reliability and cost of studies comparing to the other designs.
With our proposed 2-stage design, when γ 0 is higher than the true ROC(0.2), the continuation rate increases as sample size decreases. This is because when sample size is large, our estimate based on stage 1 is less variable, and the confidence interval is less likely to cover γ 0 ; while with small sample size, we are less confident about stage 1 estimates and thus more likely to continue to stage 2. Therefore, our proposed continuation rules takes the uncertainty in the initial evaluation into account. For the 3 estimators discussed before, i.e. ROC all (0.2), ROC s2 (0.2) and ROC cond (0.2), their performances are as expected. ROC all (0.2) gives the highest estimates among the 3, while the standard error is low. The overestimation is obvious, 
2).
When sample size is small (n = 400, 200), the underestimation due to bias in logistic parameter estimates offsets the overestimation due to ignoring the early stopping possibility, leading to a small bias in ROC all (0.2). On the other hand, ROC s2 (0.2) and ROC cond (0.2) are lower than the true ROC(0.2) as expected, but ROC cond (0.2) still has the smallest standard error. Although in these settings, ROC s2 (0.2) and ROC cond (0.2) are biased for the true ROC(0.2) under optimal risk model with β, they are unbiased estimates for the ROC(0.2) under suboptimal risk model withβ s2 andβ cond .
We also conducted a simulation study with 33% subjects assigned to stage 1 and remaining to stage 2. Results based on 1000 simulation replications are summarized in Table 2 of the supplementary material available at Biostatistics online. When stage 1 sample size is smaller, we are less likely to terminate a study for futility. For a study that continues to stage 2, ROC cond (0.2) is still more accurate than ROC all (0.2) and more efficient than ROC s2 (0.2).
We now compare the performances of the proposed estimate with and without parametric distribution specification. We let k = 4, and With this data structure, the optimal risk model has β = (0.23, 0.23, 0.23, 0.86), and ROC(0.2) is 0.602. We applied both the logistic regression approach and the parametric bootstrap approach to the simulated datasets. Simulation results of ROC cond (0.2) based on 1000 replications are summarized in Table 2 . With both approaches, ROC cond (0.2) provides estimates that are close to the true value when sample size is large. As sample size decreases, both approaches are associated with some bias. However, this bias is larger with the logistic regression approach as expected, asβ from logistic regression is more sensitive to small sample sizes. Standard errors are smaller with parametric approach in all scenarios. This leads to a lower continuation rate when γ 0 is high, which is desirable as more samples will be saved.
Simulation results with unequal variances based on 1000 replications are summarized in Table 3 . Here, we generated data similarly as in the equal variance scenario, but let Under this data structure, the true ROC(0.2) is 0.607. As expected, ROC cond (0.2) in logistic regression approach is biased even when sample size is large, while with the binormal parametric approach bias is negligible with large sample size. As sample size decreases, neither approach provides satisfactory estimates, as logistic regression approach suffers from both model mis-specification and parameter estimation bias with small sample size, and the parametric approach depends on the accuracy of binormal model parameter estimates. Standard errors are smaller with the parametric approach, which also leads to lower continuation rate with high γ 0 .
In summary, our proposed 2-stage design has the highest potential to save samples when the total planned sample size is large. In our various simulation settings, we can save up to 35% of available samples. When the total sample size is relatively small, the number of samples saved from this 2-stage design is limited regardless, and it might be preferable to use the fixed-sample design. Conditional estimators of the performance parameters are accurate and efficient.
PROSTATE CANCER BIOMARKER APPLICATION
In this section, we apply the proposed group sequential design and the estimators to a multi-center EDRN prostate cancer biomarker validation study. Prostate Specific Antigen (PSA) is widely used for prostate cancer screening, but has limited sensitivity and specificity. Prostate Cancer Antigen 3 (PCA3) is a urinary biomarker that is approved by the Food and Drug Administration as a risk assessment biomarker of prostate cancer. The objective of this study is to examine the performance improvement from adding PCA3 to the standard clinical PSA biomarker in detecting high-grade prostate cancer (i.e. Gleason score 7). Since most low-grade prostate cancer are indolent, a reliable mean of distinguishing between low-and highgrade prostate cancers may allow some patients to avoid biopsies and other invasive treatments such as radical prostatectomy.
This study includes 859 men from 11 EDRN centers who are scheduled for a prostate biopsy due to some previous prostate cancer related indications. Among these patients, 562 patients were presenting for their initial biopsy, while the other 297 patients had a prior negative biopsy. PSA and PCA3 measures were taken prior to biopsy. Gleason scores were assessed by pathologists at each clinical center based on biopsy samples. We analyze the initial biopsy patients and the repeat biopsy patients separately. Since these patients were scheduled for biopsy for indications related to prostate cancer, we want the combined biomarker test to have high sensitivity to avoid missing high-grade prostate cancer, while improving specificity so that more low-grade patients can avoid biopsy and treatment. Hence we use ROC −1 (0.95) to evaluate the performance of combined test. Both PSA and PCA3 measures are log-transformed to achieve approximate normality in both the high-grade and low-grade groups.
When we use PSA to distinguish high-and low-grade prostate cancer patients, ROC −1 (0.95) is 0.144 for the initial biopsy group and 0.149 for the repeat biopsy group. With PCA3 only, it is 0.235 and 0.406, respectively. PCA3 is a somewhat better marker to use in clinical practice, compared with PSA. To investigate if combining PSA and PCA3 will improve performance, we use the higher performance of the 2 biomarkers applied individually as the minimal acceptance criteria, that is γ 0 equals to 0.235 and 0.406 for the 2 patient groups. For each biopsy group, we randomly assign half of the patients to stage 1. Results are summarized in Table 4 .
For the initial biopsy group, we first use the logistic regression approach. cond (0.95) reduces bias due to the resampling stage 1 and 2 data in the outer bootstrap steps, and is expected to have more stable performance. We also investigated the parametric bootstrap approach. The sample covariance matrices are slightly different for the 2 outcome groups, so we allowed for unequal variances. The estimated cond (0.95) is quite similar to that with logistic regression approach, but again with a narrower confidence interval. This also suggests that a linear combination is likely to be suitable for these 2 biomarkers. Similar analysis were conducted for the repeat biopsy group. With randomly selected stage 1 data, both approaches suggests continuing to stage 2. Upon study completion, we estimate 
DISCUSSION
Cost-effective designs are urgently needed for biomarker studies, as the number of biomarkers potentially useful in clinical practice has increased dramatically with technology developments. Group sequential methods have a natural place due to this early termination for futility possibility. Previous literature has discussed the use of a group sequential strategy for inference upon study completion with a single biomarker. In this manuscript, we extended existing methods to a phase 2 biomarker panel development study. We described a 2-stage study design, and proposed conditional estimators that take early termination into account. Although this 2-stage design has already been used in EDRN to conserve samples and minimize cost, its properties and the corresponding estimators following study completion have not been studied systematically. We compared this study design with fixed-sample design and a previously proposed 2-stage design that does not allow for updating the risk model. The proposed design has the ability to save samples when candidate biomarkers are not promising, while providing an efficient conditional estimate of performance when they are promising.
Resampling procedures are typically needed to calculate the proposed conditional estimates. In this manuscript, we provided an alternative approach if a multivariate binormal distribution can be assumed. As mentioned, our method also applies to other families of parametric distributions. Under parametric assumptions, one can expect the performance parameter estimates to be more efficient, and computational burden may be reduced.
Here, we restricted the application to a relatively small number of biomarkers. This is of practical importance for studies focusing on biomarkers that have strong evidence for use in clinical practice. Hence we defined the rejection criterion in terms of the 95% confidence interval, which is lenient in order not to miss potentially useful panels. In other situations where the potential utility of candidate markers not evident, we could use a stricter criterion, for example, by considering an approach similar to that of the Koopmeiners and Vogal approach, i.e. terminating the study when the point estimate is below a pre-specified threshold. Then we only need to modify how we define C [ j] in the outer bootstrap procedure, and all the other steps will follow.
When the candidate panel is of high-dimensional, one needs to consider model selection procedures. Our proposed 2-stage design can be extended for use in conjunction with dimension reduction. For example, we can replace the logistic regression model with a LASSO model (Tibshirani, 1996) in both stages 1 and 2. For studies that continue to study completion, extra steps are needed to obtain conditional estimators of performance parameters. That is, when we perform the outer bootstrap procedure, different biomarkers can be selected each time. At the end of bootstrap replications, we may consider selecting the final model by restricting to those markers that appear enough number of times in the bootstrap replications. This selection needs to be taken into account in the conditional estimators. The methods for doing so are beyond the scope of this paper but well worth exploring. In the simulation, we compared our results with the Koopmeiners and Vogel approach. In the setting of validating a small number of markers with strong evidence, the Koopmeiners and Vogel approach suffers from high rejection rate and may not efficiently use all information. However, under a higher-dimensional panel setting of their original proposal, their approach is easy to use and performs well.
Our proposed 2-stage design and conditional estimators can be extended to assess the performance of a biomarker panel when outcome is a censored failure time. Instead of a disease indicator D, the outcome is (Y, δ) , where Y = min(T, C) is the minimum of the actual event time T and the independent censoring time C, and δ = I (T C). At a specific time point τ , we can define a binary outcome D(τ ) = I (T τ ). With censoring present, a logistic regression with inverse probability weighting can be used as discussed in Zheng and others (2006) : subjects censored before τ will have weight 0, subjects having events before τ are weighted by 1/P(C > Y |X, Y ), and those still at risk at τ are weighted by 1/P(C > τ |X). With the 2-stage design, we can replace the standard logistic regression with this re-weighted logistic regression in
Step B of the inner bootstrap procedure. The probability in the weighting can be estimated as described in Zheng and others (2006) , with the data from current cohort under investigation. The conditional estimators can be applied with a valid ROC(t) estimate in each stage.
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